Cancer Network
Spotlight
Clinical
News
Media
Conferences
Publications
Resources
Subscribe
Events

  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • CancerNetwork.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2021 MJH Life Sciences and Cancer Network. All rights reserved.

Spotlight
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Around the Practice
  • Chronic Lymphocytic Leukemia
  • Head & Neck Cancer
  • HER2-Positive Breast Cancer
  • K-Cast
  • Multiple Myeloma
  • Non-Small Cell Lung Cancer (NSCLC)
  • Ovarian Cancer
  • Prostate Cancer
  • Renal Cell Carcinoma
  • Small Cell Lung Cancer (SCLC)
ClinicalSee All >
  • Brain Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Gynecologic Cancer
  • Hematology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Pediatric Cancers
  • Skin Cancer
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • CancerNetwork.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.

Merck to Donate 3 Million Doses of Cervical Cancer Vaccine to Third World Nations

October 1, 2007
Oncology, ONCOLOGY Vol 21 No 11, Volume 21, Issue 11

Merck & Co., Inc. has committed to donate at least 3 million doses of quadrivalent human papillomavirus (HPV types 6, 11, 16, 18) recombinant vaccine (Gardasil), the cervical cancer vaccine, for use in demonstration projects in lowest-income nations throughout the world.

Merck & Co., Inc. has committed to donate at least 3 million doses of quadrivalent human papillomavirus (HPV types 6, 11, 16, 18) recombinant vaccine (Gardasil), the cervical cancer vaccine, for use in demonstration projects in lowest-income nations throughout the world. The program, part of Merck's comprehensive approach to bringing newer vaccines to the developing world, was announced recently as Merck's commitment at the Clinton Global Initiative.

"By donating 3 million doses of Gardasil over the next 5 years, we are committing to the vaccination of 1 million females against cervical cancer, a disease that takes the lives of nearly 250,000 women each year," said Margaret G. McGlynn, president, Merck Vaccines and Infectious Disease. "Our company is fully committed to making Gardasil available to those who need it, and we will continue to work with our partners in the international community to develop sustainable solutions to bring Gardasil and other vaccines to the developing world."

Merck is pursuing a systematic approach to the global introduction of two of its vaccines, the live, oral pentavalent rotavirus vaccine (RotaTeq) and the HPV vaccine, and is committed to making both vaccines available to developing world nations at dramatically lower prices at which Merck will not profit.

Related Content:

Cervical Cancer | Gynecologic cancer